Health

Pharmaceutical Deal

Updated 2026-06-01 12:35 UTC 1 source Neutral

Servier is acquiring an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion, advancing research in this debilitating condition.

Coverage timeline — 1 article

STAT News

STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

2026-06-01 12:31 UTC